Form 4: Amgen EVP Jonathan Graham Executes Stock Options and Sells Shares
SEC Form 4 Filing
Executive Vice President and General Counsel & Secretary of Amgen, Jonathan P. Graham, exercised stock options and sold shares of common stock on February 7, 2025.
Summary
- On February 7, 2025, Jonathan P. Graham, EVP & General Counsel & Secretary of Amgen Inc., exercised stock options to acquire 25,045 shares of Amgen common stock at a price of $156.35 per share.
- Simultaneously, Graham sold 25,045 shares of Amgen common stock at an average price of $293.1173 per share.
- Following these transactions, Graham directly owns 28,987 shares of Amgen common stock, which includes 634 Dividend Equivalents (DEs).
Sentiment
Score: 5
Explanation: Neutral sentiment as it reflects a standard executive stock option exercise and sale, with no explicit positive or negative implications for the company's performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common for executives who receive stock options as part of their compensation. The market will likely interpret this as a standard part of executive compensation and portfolio management.
Comparison to Industry Standards
- Executive stock option exercises and sales are a common practice across publicly traded companies, particularly in the pharmaceutical and biotechnology sectors.
- Companies like Pfizer, Johnson & Johnson, and Merck also see similar Form 4 filings from their executives regularly.
- The timing and volume of these transactions are often scrutinized by investors for insights into executive sentiment regarding the company's future prospects, but are generally considered part of normal compensation practices.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders.
- Shareholders may view the transaction as part of the executive's compensation and portfolio diversification strategy.
Key Dates
| Date | Description |
|---|---|
| 05/03/2018 | Date stock options became exercisable |
| 05/03/2026 | Expiration date of stock options |
| 02/07/2025 | Date of stock option exercise and share sale |
| 02/09/2025 | Date of Form 4 filing |
Keywords
Amgen, Jonathan Graham, Stock Options, SEC Form 4, Insider Trading, AMGN, Executive Compensation, Share Sale, Dividend Equivalents
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.